Phase III randomized study of fotemustine and dacarbazine versus ...

No significant improvement in outcomes were observed with the addition of either fotemustine or IFN-α2b to dacarbazine.

In a phase III study, fotemustine was associated with a higher overall response rate (ORR) than dacarbazine in the intention-to-treat (ITT) ...

Phase III randomized study of fotemustine and dacarbazine versus ...

In the adjuvant setting, a meta-analysis of randomized melanoma trials using a wide range of IFN dose regimens revealed that the benefits of IFN ...

(PDF) Phase III randomized study of fotemustine and dacarbazine ...

PDF | The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced ...

Fotemustine Compared With Dacarbazine in Patients With ...

Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. S D Luikart et al.,; +0 ...

Fotemustine and dacarbazine plus recombinant interferon alpha2a ...

E Bajetta et al. Phase II study of Interferon alpha-2a and dacarbazine in advanced melanoma ... Multicenter randomized trial of dacarbazine alone or in ...

fotemustine (FM) and dacarbazine (DTIC) versus DTIC ± interferon α ...

fotemustine (FM) and dacarbazine (DTIC) versus DTIC ± interferon α in advanced malignant melanoma: A phase III study of the Southern Italy ...

A randomized phase III study comparing dacarbazine, BCNU ...

... Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 ...

Phase III randomized study of fotemustine and dacarbazine versus ...

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. by Antonio Daponte ...

(PDF) Fotemustine Compared With Dacarbazine in Patients With ...

... Randomized phase III study of temozolomide. versus dacarbazine in the treatment of patients. with advanced metastatic malignant melanoma. J ...

Fotemustine Compared With Dacarbazine in Patients With ... - OUCI

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study ... Phase III randomized study of fotemustine and ...

Treatments for metastatic melanoma: Synthesis of evidence from ...

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study ... randomized trial of the Dartmouth regimen versus ...

Phase 3 study of docosahexaenoic acid–paclitaxel versus ...

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study ... randomized phase III study (EORTC 18032).

Survival with dacarbazine and fotemustine in newly diagnosed ...

... study criteria or withdrawal of consent. Modification of ... Phase II study of fotemustine in recurrent supratentorial malignant gliomas.

DCRB - Cancer Care Ontario

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. JCO 2004; 22:1118-25. Therapy for metastatic ...

Clinical Trials Using Dacarbazine - NCI

This phase III trial compares the effect of adding chemotherapy (doxorubicin or ... This is a randomized, controlled, multicenter, open-label Phase 3 ...

Multicenter phase III randomized trial of polychemotherapy (CVD ...

In this phase III trial, we compared the effects of CT [cisplatin, vindesine and dacarbazine (CVD)] with those of concurrent biochemotherapy (bioCT)

An Overview of Fotemustine in High‐Grade Gliomas: From Single ...

In a recent Dutch phase II randomized study on recurrent glioblastoma (BELOB trial) [30] presented at American Society of Clinical Oncology ( ...

Biochemotherapy in the treatment of metastatic melanoma in ...

... randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. ... Phase III Randomized Clinical Trial. J Clin ...

Cisplatin, dacarbazine, and fotemustine plus interferon α in patients ...

Herein, the authors report the results of a Phase II trial with this regimen. METHODS. From June 1996 to February 1999, 64 patients with ...